TAPUR: Testen der Verwendung von von der Food and Drug Administration (FDA) zugelassenen Arzneimitteln, die auf eine bestimmte Anomalie in einem Tumorgen bei Menschen mit Krebs im fortgeschrittenen Stadium abzielen (TAPUR)
Targeted Agent and Profiling Utilization Registry (TAPUR)-Studie
The purpose of the study is to learn from the real world practice of prescribing targeted therapies to patients with advanced cancer whose tumor harbors a genomic variant known to be a drug target or to predict sensitivity to a drug.
NOTE: Due to character limits, the arms section does NOT include all TAPUR Study relevant biomarkers. For additional information, contact TAPUR@asco.org, or if a patient, your nearest participating TAPUR site (see participating centers).
********************************************************************
Results in publication or poster presentation format are posted as they become available for individual cohorts at www.tapur.org/news. The results may be accessed at any time. All results will be made available on clinicaltrials.gov at the end of the study. Indexing of available results on PubMed is in progress.
********************************************************************
Studienübersicht
Status
Status
Bedingungen
Bedingungen
Intervention / Behandlung
Intervention / Behandlung
- Arzneimittel: Sunitinib (CLOSED TO ENROLLMENT)
- Arzneimittel: Trastuzumab and Pertuzumab (CLOSED TO ENROLLMENT)
- Arzneimittel: Vemurafenib and Cobimetinib (CLOSED TO ENROLLMENT)
- Arzneimittel: Olaparib (CLOSED TO ENROLLMENT)
- Arzneimittel: Nivolumab and Ipilimumab (CLOSED TO ENROLLMENT)
- Arzneimittel: Abemaciclib (CLOSED TO ENROLLMENT)
- Arzneimittel: Talazoparib (CLOSED TO ENROLLMENT)
- Arzneimittel: Atezolizumab and Talazoparib (CLOSED TO ENROLLMENT)
- Arzneimittel: Tucatinib plus Trastuzumab Subcutaneous (SC) (CLOSED TO ENROLLMENT)
- Arzneimittel: Futibatinib
- Arzneimittel: Dabrafenib plus Trametinib
- Arzneimittel: Fam-Trastuzumab Deruxtecan-Nxki (TDxD)
Detaillierte Beschreibung
The Targeted Agent and Profiling Utilization Registry (TAPUR) Study is a non-randomized clinical trial that aims to describe the safety and efficacy of commercially available, targeted anticancer drugs prescribed for treatment of patients with advanced cancer that has a potentially actionable genomic variant. TAPUR will study Food and Drug Administration (FDA)-approved targeted therapies that are contributed by collaborating pharmaceutical companies, catalogue the choice of molecular profiling test by clinical oncologists and develop hypotheses for additional clinical trials.
Studientyp
Studientyp
Einschreibung (Geschätzt)
Einschreibung
Phase
Phase
- Phase 2
Kontakte und Standorte
Studienkontakt
Studienkontakt
- Name: Laurie Smith, MA
- Telefonnummer: www.tapur.org
- E-Mail: tapur@asco.org
Studienorte
-
-
Puerto Rico
-
Cayey, Puerto Rico, Puerto Rico, 00737
- Rekrutierung
- PanOncology Trials
-
Kontakt:
- Natalia Ortiz
- Telefonnummer: 787-407-3333
- E-Mail: natalia.ortiz@panoncologytrials.com
-
Hauptermittler:
- Maria Cruz Correa, MD
-
Dorado, Puerto Rico, Puerto Rico, 00646
- Rekrutierung
- PanOncology Trials
-
Kontakt:
- Natalia Ortiz
- Telefonnummer: 787-407-3333
- E-Mail: natalia.ortiz@panoncologytrials.com
-
Hauptermittler:
- Maria Cruz Correa, MD
-
Manati, Puerto Rico, Puerto Rico, 00674
- Rekrutierung
- PanOncology Trials
-
Kontakt:
- Natalia Ortiz
- Telefonnummer: 787-407-3333
- E-Mail: natalia.ortiz@panoncologytrials.com
-
Hauptermittler:
- Maria Crus Correa, MD
-
Mayagüez, Puerto Rico, Puerto Rico, 00680
- Rekrutierung
- PanOncology Trials
-
Kontakt:
- Natalia Ortiz
- Telefonnummer: 787-407-3333
- E-Mail: natalia.ortiz@panoncologytrials.com
-
Hauptermittler:
- Maria Cruz Correa, MD
-
Ponce, Puerto Rico, Puerto Rico, 00730
- Rekrutierung
- PanOncology Trials
-
Kontakt:
- Natalia Ortiz
- Telefonnummer: 787-407-3333
- E-Mail: natalia.ortiz@panoncologytrials.com
-
Hauptermittler:
- Maria Cruz Correa, MD
-
San Juan, Puerto Rico, Puerto Rico, 00909
- Rekrutierung
- PanOncology Trials
-
Kontakt:
- Natalia Ortiz
- Telefonnummer: 787-407-3333
- E-Mail: natalia.ortiz@panoncologytrials.com
-
Hauptermittler:
- Maria Cruz Correa, MD
-
San Juan, Puerto Rico, Puerto Rico, 00935
- Rekrutierung
- PanOncology Trials
-
Kontakt:
- Natalia Ortiz
- Telefonnummer: 787-407-3333
- E-Mail: natalia.ortiz@panoncologytrials.com
-
Hauptermittler:
- Maria Cruz Correa, MD
-
-
-
-
Alabama
-
Birmingham, Alabama, Vereinigte Staaten, 35294
- Rekrutierung
- University of Alabama at Birmingham Comprehensive Cancer Center
-
Hauptermittler:
- Mehmet Akce, MD
-
Kontakt:
- Kun Yuan
- Telefonnummer: 205-644-2584
- E-Mail: kunyuan@uabmc.edu
-
-
Arizona
-
Phoenix, Arizona, Vereinigte Staaten, 85338
- Rekrutierung
- Cancer Treatment Centers of America-Phoenix
-
Hauptermittler:
- Sagun Shrestha, MD
-
Kontakt:
- Alex Lizzul
- Telefonnummer: 602-872-5654
- E-Mail: alizzul@coh.org
-
-
California
-
Auburn, California, Vereinigte Staaten, 95602
- Rekrutierung
- Sutter Auburn
-
Kontakt:
- Kirsten Babski
- Telefonnummer: 916-878-4990
- E-Mail: BabskiK@sutterhealth.org
-
Hauptermittler:
- Nitin Rohatgi, MD
-
Berkeley, California, Vereinigte Staaten, 94705
- Rekrutierung
- Sutter Alta Bates
-
Kontakt:
- Christopher Tang
- Telefonnummer: 510-204-3428
- E-Mail: Christopher.Tang@sutterhealth.org
-
Hauptermittler:
- Nitin Rohatgi, MD
-
Los Angeles, California, Vereinigte Staaten, 90025
- Rekrutierung
- The Angeles Clinic and Research Institute, A Cedars-Sinai Affiliate
-
Kontakt:
- Teri Mata
- Telefonnummer: 310-231-2115
- E-Mail: tmata@theangelesclinic.org
-
Hauptermittler:
- Omid Hamid, MD
-
Oakland, California, Vereinigte Staaten, 94611
- Rekrutierung
- Kaiser Permanente - Oakland Medical Center
-
Kontakt:
- Desiree Goldstein
- E-Mail: desiree.goldstein@kp.org
-
Hauptermittler:
- Jennifer M Suga, MD
-
Palo Alto, California, Vereinigte Staaten, 94301
- Rekrutierung
- Sutter Palo Alto Medical Foundation: Palo Alto
-
Kontakt:
- E-Mail: clinicaltrials@pamf.org
-
Roseville, California, Vereinigte Staaten, 95661
- Rekrutierung
- Kaiser Permanente - Roseville Medical Center
-
Kontakt:
- Desiree Goldstein
- E-Mail: desiree.goldstein@kp.org
-
Hauptermittler:
- Jennifer M Suga, MD
-
Roseville, California, Vereinigte Staaten, 95661
- Rekrutierung
- Sutter Roseville
-
Kontakt:
- Kirsten Babski
- Telefonnummer: 916-878-4990
- E-Mail: BabskiK@sutterhealth.org
-
Hauptermittler:
- Nitin Rohatgi, MD
-
Sacramento, California, Vereinigte Staaten, 95814
- Rekrutierung
- Kaiser Permanente - Sacramento Medical Center
-
Kontakt:
- Desiree Goldstein
- E-Mail: desiree.goldstein@kp.org
-
Hauptermittler:
- Jennifer M Suga, MD
-
Sacramento, California, Vereinigte Staaten, 95816
- Rekrutierung
- Sutter Sacramento
-
Kontakt:
- E-Mail: SIMR@sutterhealth.org
-
Hauptermittler:
- Nitin Rohatgi, MD
-
San Francisco, California, Vereinigte Staaten, 94115
- Rekrutierung
- California Pacific Medical Center Research Institute
-
Kontakt:
- Telefonnummer: 415-600-1654
- E-Mail: clinicalresearch@sutterhealth.org
-
Hauptermittler:
- Nitin Rohatgi, MD
-
San Francisco, California, Vereinigte Staaten, 94080
- Rekrutierung
- Kaiser Permanente - South San Francisco Medical Center
-
Kontakt:
- Desiree Goldstein
- E-Mail: desiree.goldstein@kp.org
-
Hauptermittler:
- Jennifer M Suga, MD
-
San Francisco, California, Vereinigte Staaten, 94115
- Rekrutierung
- Kaiser Permanente - San Francisco Medical Center
-
Kontakt:
- Desiree Goldstein
- E-Mail: desiree.goldstein@kp.org
-
Hauptermittler:
- Jennifer M Suga, MD
-
San Francisco, California, Vereinigte Staaten, 94115
- Rekrutierung
- Sutter Cancer Research Consortium
-
Kontakt:
- Laurel Brechtel
- Telefonnummer: 415-600-1654
- E-Mail: BrechtLa@cpmcri.org
-
Hauptermittler:
- Stacy D'Andre, MD
-
San Jose, California, Vereinigte Staaten, 95119
- Rekrutierung
- Kaiser Permanente - San Jose Medical Center
-
Kontakt:
- Desiree Goldstein
- E-Mail: desiree.goldstein@kp.org
-
Hauptermittler:
- Jennifer M Suga, MD
-
San Leandro, California, Vereinigte Staaten, 94577
- Rekrutierung
- Kaiser Permanente - San Leandro Medical Center
-
Kontakt:
- Desiree Goldstein
- E-Mail: desiree.goldstein@kp.org
-
Hauptermittler:
- Jennifer M Suga, MD
-
Santa Barbara, California, Vereinigte Staaten, 93105
- Rekrutierung
- Sutter Sansum Clinic
-
Hauptermittler:
- Nitin Rohatgi, MD
-
Kontakt:
- Selina Perez
- Telefonnummer: 831-458-5837
- E-Mail: Selina.Perez@sutterhealth.org
-
Santa Clara, California, Vereinigte Staaten, 95051
- Rekrutierung
- Kaiser Permanente - Santa Clara Medical Center
-
Kontakt:
- Desiree Goldstein
- E-Mail: desiree.goldstein@kp.org
-
Hauptermittler:
- Jennifer M Suga, MD
-
Santa Cruz, California, Vereinigte Staaten, 95065
- Rekrutierung
- Sutter Palo Alto Medical Foundation: Santa Cruz
-
Kontakt:
- E-Mail: clinicaltrials@pamf.org
-
Santa Cruz, California, Vereinigte Staaten, 994538
- Rekrutierung
- Sutter Palo Alto Medical Foundation: Fremont
-
Kontakt:
- E-Mail: clinicaltrials@pamf.org
-
Sunnyvale, California, Vereinigte Staaten, 94086
- Rekrutierung
- Sutter Palo Alto Medical Foundation: Sunnyvale
-
Kontakt:
- E-Mail: clinicaltrials@pamf.org
-
Vallejo, California, Vereinigte Staaten, 94589
- Rekrutierung
- Kaiser Permanente - Vallejo Medical Center
-
Kontakt:
- Desiree Goldstein
- E-Mail: desiree.goldstein@kp.org
-
Hauptermittler:
- Jennifer M. Suga, MD
-
Walnut Creek, California, Vereinigte Staaten, 94596
- Rekrutierung
- Kaiser Permanente - Walnut Creek Medical Center
-
Kontakt:
- Desiree Goldstein
- E-Mail: desiree.goldstein@kp.org
-
Hauptermittler:
- Jennifer M Suga, MD
-
-
Connecticut
-
Bridgeport, Connecticut, Vereinigte Staaten, 06606
- Rekrutierung
- Saint Vincent's Medical Center (SVMC)
-
Kontakt:
- Telefonnummer: 860-972-4700
- E-Mail: CancerResearchSupport@hhchealth.org
-
Hauptermittler:
- Wylie Hosmer, MD
-
Hartford, Connecticut, Vereinigte Staaten, 06102
- Rekrutierung
- Hartford Hospital
-
Kontakt:
- Telefonnummer: 860-972-4700
- E-Mail: CancerResearchSupport@hhchealth.org
-
Hauptermittler:
- Wylie Hosmer, MD
-
Meriden, Connecticut, Vereinigte Staaten, 06451
- Rekrutierung
- Midstate Medical Center (MSMC)
-
Kontakt:
- Telefonnummer: 860-972-4700
- E-Mail: CancerResearchSupport@hhchealth.org
-
Hauptermittler:
- Wylie Hosmer, MD
-
New Britain, Connecticut, Vereinigte Staaten, 06053
- Rekrutierung
- The Hospital of Central Connecticut (HOCC) Cancer Center
-
Hauptermittler:
- Wylie Hosmer, MD
-
Kontakt:
- Telefonnummer: 8609724700
- E-Mail: CancerResearchSupport@hhchealth.org
-
Norwich, Connecticut, Vereinigte Staaten, 06360
- Rekrutierung
- William W. Backus Hospital
-
Kontakt:
- Telefonnummer: 860-972-4700
- E-Mail: CancerResearchSupport@hhchealth.org
-
Hauptermittler:
- Wylie Hosmer, MD
-
Torrington, Connecticut, Vereinigte Staaten, 06790
- Rekrutierung
- Charlotte Hungerford
-
Kontakt:
- Telefonnummer: 860-972-4700
- E-Mail: CancerResearchSupport@hhchealth.org
-
Hauptermittler:
- Wylie Hosmer, MD
-
Willimantic, Connecticut, Vereinigte Staaten, 06226
- Rekrutierung
- Windham Hospital (WH)
-
Kontakt:
- Telefonnummer: 860-972-4700
- E-Mail: CancerResearchSupport@hhchealth.org
-
Hauptermittler:
- Wylie Hosmer, MD
-
-
Florida
-
Altamonte Springs, Florida, Vereinigte Staaten, 32701
- Aktiv, nicht rekrutierend
- Florida Cancer Specialists North / Sarah Cannon Research Institute
-
Aventura, Florida, Vereinigte Staaten, 33180
- Rekrutierung
- University of Miami/Sylvester Cancer Institute - Aventura
-
Kontakt:
- Carolina Troche, BS
- Telefonnummer: 305-243-1481
- E-Mail: cxt582@med.miami.edu
-
Hauptermittler:
- Carmen Calfa, MD
-
Bonita Springs, Florida, Vereinigte Staaten, 34135
- Aktiv, nicht rekrutierend
- Florida Cancer Specialists South / Sarah Cannon Research Institute
-
Bradenton, Florida, Vereinigte Staaten, 34211
- Aktiv, nicht rekrutierend
- Florida Cancer Specialists South / Sarah Cannon Research Institute
-
Brandon, Florida, Vereinigte Staaten, 33511
- Aktiv, nicht rekrutierend
- Florida Cancer Specialists North / Sarah Cannon Research Institute
-
Cape Coral, Florida, Vereinigte Staaten, 33909
- Aktiv, nicht rekrutierend
- Florida Cancer Specialists South / Sarah Cannon Research Institute
-
Clearwater, Florida, Vereinigte Staaten, 33761
- Aktiv, nicht rekrutierend
- Florida Cancer Specialists North / Sarah Cannon Research Institute
-
Coral Gables, Florida, Vereinigte Staaten, 33146
- Rekrutierung
- University of Miami/Sylvester Cancer Institute - Lennar
-
Kontakt:
- Carolina Troche, BS
- Telefonnummer: 305-243-1481
- E-Mail: cxt582@med.miami.edu
-
Hauptermittler:
- Carmen Calfa, MD
-
Deerfield Beach, Florida, Vereinigte Staaten, 33442
- Rekrutierung
- University of Miami/Sylvester Cancer Institute - Deerfield Beach
-
Kontakt:
- Carolina Troche, BS
- Telefonnummer: 305-243-1481
- E-Mail: cxt582@med.miami.edu
-
Hauptermittler:
- Carmen Calfa, MD
-
Fort Lauderdale, Florida, Vereinigte Staaten, 33308
- Rekrutierung
- Holy Cross Hospital
-
Hauptermittler:
- Zdenka Segota, MD
-
Kontakt:
- Telefonnummer: 7347123671
- E-Mail: MCRCwebsitecontactform@trinity-health.org
-
Fort Myers, Florida, Vereinigte Staaten, 33901
- Aktiv, nicht rekrutierend
- Florida Cancer Specialists South / Sarah Cannon Research Institute
-
Fort Myers, Florida, Vereinigte Staaten, 33905
- Aktiv, nicht rekrutierend
- Florida Cancer Specialists South / Sarah Cannon Research Institute
-
Fort Myers, Florida, Vereinigte Staaten, 33908
- Aktiv, nicht rekrutierend
- Florida Cancer Specialists South / Sarah Cannon Research Institute
-
Gainesville, Florida, Vereinigte Staaten, 32610
- Rekrutierung
- University of Florida Health
-
Hauptermittler:
- Thomas George, MD
-
Kontakt:
- Anna Kukulka, RN, BSN
- Telefonnummer: 352-293-2551
- E-Mail: akukulka@ufl.edu
-
Gainesville, Florida, Vereinigte Staaten, 32605
- Aktiv, nicht rekrutierend
- Florida Cancer Specialists North / Sarah Cannon Research Institute
-
Largo, Florida, Vereinigte Staaten, 33770
- Aktiv, nicht rekrutierend
- Florida Cancer Specialists North / Sarah Cannon Research Institute
-
Lecanto, Florida, Vereinigte Staaten, 34461
- Aktiv, nicht rekrutierend
- Florida Cancer Specialists North / Sarah Cannon Research Institute
-
Miami, Florida, Vereinigte Staaten, 33136
- Rekrutierung
- University of Miami Sylvester Comprehensive Cancer Center
-
Kontakt:
- Carolina Troche, BS
- Telefonnummer: 305-243-1481
- E-Mail: cxt582@med.miami.edu
-
Hauptermittler:
- Carmen Calfa, MD
-
Miami, Florida, Vereinigte Staaten, 33136
- Rekrutierung
- University of Miami/Sylvester Cancer Institute - Alex's Place
-
Kontakt:
- Carolina Troche, BS
- Telefonnummer: 305-243-1481
- E-Mail: cxt582@med.miami.edu
-
Hauptermittler:
- Carmen Calfa, MD
-
Miami, Florida, Vereinigte Staaten, 33136
- Rekrutierung
- University of Miami/Sylvester Cancer Institute - Griffin Cancer Research Building
-
Kontakt:
- Carolina Troche, BS
- Telefonnummer: 305-243-1481
- E-Mail: cxt582@med.miami.edu
-
Hauptermittler:
- Carmen Calfa, MD
-
Miami, Florida, Vereinigte Staaten, 33176
- Rekrutierung
- University of Miami/Sylvester Cancer Institute - Kendall
-
Kontakt:
- Carolina Troche, BS
- Telefonnummer: 305-243-1481
- E-Mail: cxt582@med.miami.edu
-
Hauptermittler:
- Carmen Calfa, MD
-
Miami, Florida, Vereinigte Staaten, 33181
- Rekrutierung
- University of Miami/Sylvester Cancer Institute - Sole Mia
-
Kontakt:
- Carolina Troche, BS
- Telefonnummer: 305-243-1481
- E-Mail: cxt582@med.miami.edu
-
Hauptermittler:
- Carmen Calfa, MD
-
Naples, Florida, Vereinigte Staaten, 34102
- Aktiv, nicht rekrutierend
- Florida Cancer Specialists South / Sarah Cannon Research Institute
-
Ocala, Florida, Vereinigte Staaten, 34474
- Aktiv, nicht rekrutierend
- Florida Cancer Specialists North / Sarah Cannon Research Institute
-
Orange City, Florida, Vereinigte Staaten, 32763
- Aktiv, nicht rekrutierend
- Florida Cancer Specialists North / Sarah Cannon Research Institute
-
Orlando, Florida, Vereinigte Staaten, 32806
- Aktiv, nicht rekrutierend
- Florida Cancer Specialists North / Sarah Cannon Research Institute
-
Plantation, Florida, Vereinigte Staaten, 33324
- Rekrutierung
- University of Miami/Sylvester Cancer Institute - Plantation
-
Kontakt:
- Carolina Troche, BS
- Telefonnummer: 305-243-1481
- E-Mail: cxt582@med.miami.edu
-
Hauptermittler:
- Carmen Calfa, MD
-
Port Charlotte, Florida, Vereinigte Staaten, 33980
- Aktiv, nicht rekrutierend
- Florida Cancer Specialists South / Sarah Cannon Research Institute
-
Sarasota, Florida, Vereinigte Staaten, 34236
- Aktiv, nicht rekrutierend
- Florida Cancer Specialists South / Sarah Cannon Research Institute
-
Sarasota, Florida, Vereinigte Staaten, 34239
- Aktiv, nicht rekrutierend
- Florida Cancer Specialists South / Sarah Cannon Research Institute
-
St. Petersburg, Florida, Vereinigte Staaten, 33701
- Aktiv, nicht rekrutierend
- Florida Cancer Specialists North / Sarah Cannon Research Institute
-
Tampa, Florida, Vereinigte Staaten, 33607
- Aktiv, nicht rekrutierend
- Florida Cancer Specialists North / Sarah Cannon Research Institute
-
Tavares, Florida, Vereinigte Staaten, 32778
- Aktiv, nicht rekrutierend
- Florida Cancer Specialists North / Sarah Cannon Research Institute
-
The Villages, Florida, Vereinigte Staaten, 32159
- Aktiv, nicht rekrutierend
- Florida Cancer Specialists North / Sarah Cannon Research Institute
-
Trinity, Florida, Vereinigte Staaten, 34655
- Aktiv, nicht rekrutierend
- Florida Cancer Specialists North / Sarah Cannon Research Institute
-
Venice, Florida, Vereinigte Staaten, 34285
- Aktiv, nicht rekrutierend
- Florida Cancer Specialists South / Sarah Cannon Research Institute
-
Venice, Florida, Vereinigte Staaten, 34292
- Aktiv, nicht rekrutierend
- Florida Cancer Specialists South / Sarah Cannon Research Institute
-
Winter Park, Florida, Vereinigte Staaten, 32789
- Aktiv, nicht rekrutierend
- Florida Cancer Specialists North / Sarah Cannon Research Institute
-
-
Georgia
-
Atlanta, Georgia, Vereinigte Staaten, 30322
- Rekrutierung
- Emory University Winship Cancer Institute
-
Hauptermittler:
- Olatunji Alese, MD
-
Kontakt:
- Krystal Bagley
- Telefonnummer: 404-778-8670
- E-Mail: krystal.joi.bagley@emory.edu
-
Atlanta, Georgia, Vereinigte Staaten, 30265
- Rekrutierung
- Cancer Treatment Centers of America - Atlanta
-
Hauptermittler:
- Bamidele Adesunloye, MD
-
Kontakt:
- Elizabeth McKoy, RN, BSN
- Telefonnummer: 770-400-7177
- E-Mail: emckoy@coh.org
-
Savannah, Georgia, Vereinigte Staaten, 31405
- Rekrutierung
- Summit Cancer Care
-
Hauptermittler:
- Mark Taylor, MD
-
Kontakt:
- Stephanie Smith, RN, MSN, OCN
- Telefonnummer: 9128195723
- E-Mail: smiths1@sjchs.org
-
Savannah, Georgia, Vereinigte Staaten, 31405
- Rekrutierung
- Gynecologic Oncology and Surgical Specialists at the Lewis Cancer & Research Pavilion
-
Hauptermittler:
- Mark Taylor, MD
-
Kontakt:
- Stephanie Smith, RN, MSN, OCN
- Telefonnummer: 9128195723
- E-Mail: smiths1@sjchs.org
-
Savannah, Georgia, Vereinigte Staaten, 31405
- Rekrutierung
- Lewis Cancer & Research Pavilion at the Melanoma, Skin Cancer & Sarcoma Institute
-
Hauptermittler:
- Mark Taylor, MD
-
Kontakt:
- Stephanie Smith, RN, MSN, OCN
- Telefonnummer: 19128195723
- E-Mail: smiths1@sjchs.org
-
Savannah, Georgia, Vereinigte Staaten, 31405
- Rekrutierung
- Lewis Cancer & Research Pavilion
-
Kontakt:
- Stephanie Smith, RN, MSN, OCN
- Telefonnummer: 912-819-5723
- E-Mail: smiths1@sjchs.org
-
Hauptermittler:
- Mark Taylor, MD
-
-
Hawaii
-
Honolulu, Hawaii, Vereinigte Staaten, 96813
- Rekrutierung
- The Queen's Medical Center - POB I
-
Hauptermittler:
- Jared Acoba, MD
-
Kontakt:
- Tim Kelleher
- Telefonnummer: 8086918582
- E-Mail: tkelleher@queens.org
-
Honolulu, Hawaii, Vereinigte Staaten, 96813
- Rekrutierung
- The Queen's Medical Center - Punchbowl
-
Hauptermittler:
- Jared Acoba, MD
-
Kontakt:
- Tim Kelleher
- Telefonnummer: 808 691-8582
- E-Mail: tkelleher@queens.org
-
Honolulu, Hawaii, Vereinigte Staaten, 96817
- Rekrutierung
- The Queen's Medical Center - Kuakini
-
Hauptermittler:
- Jared Acoba, MD
-
Kontakt:
- Tim Kelleher
- Telefonnummer: 8086918582
- E-Mail: tkelleher@queens.org
-
‘Ewa Beach, Hawaii, Vereinigte Staaten, 96706
- Rekrutierung
- The Queen's Medical Center - West Oahu
-
Hauptermittler:
- Jared Acoba, MD
-
Kontakt:
- Tim Kelleher
- Telefonnummer: 8086918582
- E-Mail: tkelleher@queens.org
-
-
Illinois
-
Chicago, Illinois, Vereinigte Staaten, 60099
- Rekrutierung
- Cancer Treatment Centers of America-Chicago
-
Hauptermittler:
- Evan Pisick, MD
-
Kontakt:
- Office of Clinical Trials
- Telefonnummer: 847-731-1777
- E-Mail: CHIResearch@coh.org
-
-
Indiana
-
Indianapolis, Indiana, Vereinigte Staaten, 46250
- Rekrutierung
- Community Health Network (The University of Texas MD Anderson Cancer Center)
-
Hauptermittler:
- Funda Meric-Bernstam, MD
-
Kontakt:
- Kshipra Sharma, MPH, MS
- Telefonnummer: 713-745-8431
- E-Mail: Ksharma2@MDAnderson.org
-
-
Maine
-
Augusta, Maine, Vereinigte Staaten, 04330
- Rekrutierung
- Harold Alfond Center for Cancer Care
-
Kontakt:
- Sandra Neptune, BSN, RN
- Telefonnummer: 207-626-4811
- E-Mail: sandra.neptune@mainegeneral.org
-
Hauptermittler:
- Lindsay Hathaway, MD
-
Augusta, Maine, Vereinigte Staaten, 04330
- Rekrutierung
- Jackson Laboratory - Maine Cancer Genomics Initiative
-
Kontakt:
- Petra Helbig, CCRP
- Telefonnummer: 207-664-4659
- E-Mail: Petra.Helbig@jax.org
-
Hauptermittler:
- Jens Rueter, MD
-
Belfast, Maine, Vereinigte Staaten, 04915
- Rekrutierung
- Waldo County General Hospital
-
Hauptermittler:
- Roger Inhorn, MD
-
Kontakt:
- Jen - Dalton, MHA, BSN, RN
- Telefonnummer: 2072948291
- E-Mail: JDalton@mmc.org
-
Biddeford, Maine, Vereinigte Staaten, 04005
- Rekrutierung
- SMHC Cancer Care and Blood Disorders -Biddeford
-
Hauptermittler:
- Roger Inhorn, MD
-
Kontakt:
- Jen - Dalton
- Telefonnummer: 2072948291
- E-Mail: JDalton@mmc.org
-
Brewer, Maine, Vereinigte Staaten, 04412
- Rekrutierung
- Northern Light Cancer Care
-
Hauptermittler:
- Sarah Sinclair, MD
-
Kontakt:
- Carla Mancini, MHA, BSN, RN
- Telefonnummer: 207-973-5581
- E-Mail: cmancini@northernlight.org
-
Brewer, Maine, Vereinigte Staaten, 04412
- Rekrutierung
- Raish Peavey Haskell Children's Cancer and Treatment Center
-
Hauptermittler:
- Sarah Sinclair, MD
-
Kontakt:
- Carla C Mancini, RN, BSN, OCN
- Telefonnummer: 2079735581
- E-Mail: cmancini@northernlight.org
-
Brunswick, Maine, Vereinigte Staaten, 04011
- Rekrutierung
- MaineHealth Cancer Care -Brunswick
-
Hauptermittler:
- Roger Inhorn, MD
-
Kontakt:
- Jen - Dalton, MHA, BSN, RN
- Telefonnummer: 2072948291
- E-Mail: JDalton@mmc.org
-
Kennebunk, Maine, Vereinigte Staaten, 04043
- Rekrutierung
- New England Cancer Specialist
-
Hauptermittler:
- Christian Thomas, MD
-
Kontakt:
- Patricia C Collins
- Telefonnummer: 2073033422
- E-Mail: collip@newecs.org
-
Kittery, Maine, Vereinigte Staaten, 03904
- Rekrutierung
- York Hopsital Oncology & Infusion Care in Kittery
-
Hauptermittler:
- Marilyn McLaughlin, MD
-
Kontakt:
- Brenda i Kiberd, RN
- Telefonnummer: 2073616115
- E-Mail: Brenda.Kiberd@yorkhospital.com
-
Norway, Maine, Vereinigte Staaten, 04268
- Rekrutierung
- Stephens Memorial Hospital
-
Hauptermittler:
- Roger Inhorn, MD
-
Kontakt:
- Jen - Dalton, MHA, BSN, RN
- Telefonnummer: 2072948291
- E-Mail: JDalton@mmc.org
-
Rockport, Maine, Vereinigte Staaten, 04856
- Rekrutierung
- Penobscot Bay Medical Center
-
Hauptermittler:
- Roger Inhorn, MD
-
Kontakt:
- Jen - Dalton, MHA, BSN, RN
- Telefonnummer: 2072948291
- E-Mail: JDalton@mmc.org
-
Sanford, Maine, Vereinigte Staaten, 04073
- Rekrutierung
- SMHC Cancer Care and Blood Disorders -Sandford
-
Hauptermittler:
- Roger Inhorn, MD
-
Kontakt:
- Jen - Dalton, MHA, BSN, RN
- Telefonnummer: 2072948291
- E-Mail: JDalton@mmc.org
-
Scarborough, Maine, Vereinigte Staaten, 04074
- Rekrutierung
- Maine Children's Cancer Program
-
Hauptermittler:
- Roger Inhorn, MD
-
Kontakt:
- Jen - Dalton, MHA, BSN, RN
- Telefonnummer: 2072948291
- E-Mail: JDalton@mmc.org
-
Scarborough, Maine, Vereinigte Staaten, 04074
- Rekrutierung
- Maine Medical Partner's Women's Health
-
Hauptermittler:
- Roger Inhorn, MD
-
Kontakt:
- Jen - Dalton, MHA, BSN, RN
- Telefonnummer: 2072948291
- E-Mail: JDalton@mmc.org
-
Scarborough, Maine, Vereinigte Staaten, 04074
- Rekrutierung
- New England Cancer Specialist
-
Hauptermittler:
- Christian Thomas, MD
-
Kontakt:
- Patricia Collins, BA, CCRC
- Telefonnummer: 207-303-3422
- E-Mail: collip@newecs.org
-
South Portland, Maine, Vereinigte Staaten, 04106
- Rekrutierung
- MaineHealth Cancer Care -South Portland
-
Kontakt:
- Jen Dalton, MHA, BSN, RN
- Telefonnummer: 207-294-8291
- E-Mail: JDalton@mmc.org
-
Hauptermittler:
- Roger Inhorn, MD
-
Topsham, Maine, Vereinigte Staaten, 04086
- Rekrutierung
- New England Cancer Specialist
-
Hauptermittler:
- Christian Thomas, MD
-
Kontakt:
- Patricia C Collins, BA, CCRC
- Telefonnummer: 12073033422
- E-Mail: collip@newecs.org
-
Wells, Maine, Vereinigte Staaten, 04090
- Rekrutierung
- York Hospital Oncology & Infusion Care in Wells
-
Hauptermittler:
- Marilyn McLaughlin, MD
-
Kontakt:
- Brenda Kiberd, RN
- Telefonnummer: 207-361-6115
- E-Mail: Brenda.Kiberd@yorkhospital.com
-
York Village, Maine, Vereinigte Staaten, 03909
- Rekrutierung
- York Hospital Oncology & Infusion Care in York
-
Hauptermittler:
- Marilyn McLaughlin, MD
-
Kontakt:
- Brenda i Kiberd, RN
- Telefonnummer: 2073616115
- E-Mail: Brenda.Kiberd@yorkhospital.com
-
-
Michigan
-
Ann Arbor, Michigan, Vereinigte Staaten, 48109
- Aktiv, nicht rekrutierend
- University of Michigan
-
Ann Arbor, Michigan, Vereinigte Staaten, 48106
- Rekrutierung
- Trinity Health Ann Arbor Hospital
-
Hauptermittler:
- Elie Dib, MD
-
Kontakt:
- Telefonnummer: 7347123671
- E-Mail: MCRCwebsitecontactform@trinity-health.org
-
Detroit, Michigan, Vereinigte Staaten, 48236
- Rekrutierung
- Henry Ford Health Saint John Hospital
-
Hauptermittler:
- Carrie Dul, MD
-
Kontakt:
- Telefonnummer: 7347123671
- E-Mail: MCRCwebsitecontactform@trinity-health.org
-
Flint, Michigan, Vereinigte Staaten, 48503
- Rekrutierung
- Genesys Hurley Cancer Institute
-
Hauptermittler:
- Paul Adams, MD
-
Kontakt:
- Telefonnummer: 7347123671
- E-Mail: MCRCwebsitecontactform@trinity-health.org
-
Grand Rapids, Michigan, Vereinigte Staaten, 49503
- Rekrutierung
- Cancer Research Consortium of West Michigan
-
Kontakt:
- Connie Szczepanek, RN
- Telefonnummer: 616-391-1230
- E-Mail: crcwm-regulatory@crcwm.org
-
Hauptermittler:
- Kathleen J. Yost, MD
-
Lansing, Michigan, Vereinigte Staaten, 48912
- Rekrutierung
- University of Michigan Health - Sparrow Lansing
-
Hauptermittler:
- Gordan Srkalovic, MD
-
Kontakt:
- Telefonnummer: 7347123671
- E-Mail: MCRCwebsitecontactform@trinity-health.org
-
Livonia, Michigan, Vereinigte Staaten, 48154
- Rekrutierung
- Trinity Health Livonia Hospital
-
Hauptermittler:
- Amit Mohindra, MD
-
Kontakt:
- Telefonnummer: 7347127251
- E-Mail: MCRCwebsitecontactform@trinity-health.org
-
Pontiac, Michigan, Vereinigte Staaten, 48341
- Rekrutierung
- Trinity Health Oakland Hospital
-
Hauptermittler:
- Julie Goodman, MD
-
Kontakt:
- Telefonnummer: 7347123671
- E-Mail: MCRCwebsitecontactform@trinity-health.org
-
Saginaw, Michigan, Vereinigte Staaten, 48601
- Rekrutierung
- MyMichigan Medical Center Saginaw
-
Hauptermittler:
- Nicholas Damico, MD
-
Kontakt:
- Telefonnummer: 7347123671
- E-Mail: MCRCwebsitecontactform@trinity-health.org
-
Traverse City, Michigan, Vereinigte Staaten, 48341
- Rekrutierung
- Michigan Cancer Research Consortium
-
Hauptermittler:
- Philip Stella, MD
-
Kontakt:
- Beth LaVasseur, RN, MS
- Telefonnummer: 734-712-7251
- E-Mail: Beth.LaVasseur@stjoeshealth.org
-
Kontakt:
- Telefonnummer: 877-590-5995
-
Warren, Michigan, Vereinigte Staaten, 48093
- Rekrutierung
- Henry Ford Health Warren Hospital
-
Hauptermittler:
- Carrie Dul, MD
-
Kontakt:
- Telefonnummer: 7347123671
- E-Mail: MCRCwebsitecontactform@trinity-health.org
-
-
Nebraska
-
Omaha, Nebraska, Vereinigte Staaten, 68198
- Rekrutierung
- University of Nebraska Medical Center
-
Hauptermittler:
- Alissa Marr, MD
-
Kontakt:
- Micki Bethea, BS
- Telefonnummer: 402-559-8011
- E-Mail: mbethea@unmc.edu
-
-
New Hampshire
-
Concord, New Hampshire, Vereinigte Staaten, 03103
- Rekrutierung
- NH Oncology - Hematology, PA
-
Kontakt:
- Ali Fleury
- Telefonnummer: 6033146888
- E-Mail: A.Fleury@nhoh.com
-
Hauptermittler:
- Michael Buff, MD
-
Manchester, New Hampshire, Vereinigte Staaten, 03103
- Rekrutierung
- Solinsky Center for Cancer Care
-
Kontakt:
- Ali Fleury, BA, CCRP
- Telefonnummer: 603-314-6888
- E-Mail: A.Fleury@nhoh.com
-
Hauptermittler:
- Michael Buff, MD
-
Portsmouth, New Hampshire, Vereinigte Staaten, 03801
- Rekrutierung
- New England Cancer Specialist
-
Hauptermittler:
- Christian Thomas, MD
-
Kontakt:
- Patricia C Collins, BA, CCRC
- Telefonnummer: 2073033422
- E-Mail: collip@newecs.org
-
-
New Mexico
-
Albuquerque, New Mexico, Vereinigte Staaten, 87110
- Rekrutierung
- Presbyterian Kaseman Hospital
-
Hauptermittler:
- Bernard Tawfik, MD
-
Kontakt:
- Monique Robertson, RN
- Telefonnummer: (505)- 559-6100
- E-Mail: mrobertso2@phs.org
-
Albuquerque, New Mexico, Vereinigte Staaten, 87102
- Rekrutierung
- Lovelace Medical Center - Saint Joseph Square
-
Hauptermittler:
- Bernard Tawfik, MD
-
Kontakt:
- Leslie Byatt
- Telefonnummer: (505) -925-0366
- E-Mail: lpbyatt@salud.unm.edu
-
Albuquerque, New Mexico, Vereinigte Staaten, 87131
- Rekrutierung
- The University of New Mexico Comprehensive Cancer Center
-
Hauptermittler:
- Bernard Tawfik, MD
-
Kontakt:
- Sheri Westgate, RN-BSN, OCN
- Telefonnummer: (505) -925-0383
- E-Mail: swestgate@salud.unm.edu
-
Las Cruces, New Mexico, Vereinigte Staaten, 88011
- Rekrutierung
- Memorial Medical Center
-
Hauptermittler:
- Bernard Tawfik, MD
-
Kontakt:
- Kim Hoffman, RN
- Telefonnummer: (575)- 556-6545
- E-Mail: kim.hoffman@lpnt.net
-
Rio Rancho, New Mexico, Vereinigte Staaten, 87124
- Rekrutierung
- Presbyterian Rust Medical Center
-
Hauptermittler:
- Bernard Tawfik, MD
-
Kontakt:
- Andrea Yost
- Telefonnummer: (505) -253-7878
- E-Mail: ayost3@phs.org
-
-
New York
-
Lake Success, New York, Vereinigte Staaten, 11042
- Rekrutierung
- Northwell Health Monter Cancer Center
-
Kontakt:
- Mary Agnes Templeton
- Telefonnummer: 516-734-8979
- E-Mail: mtempleton@northwell.edu
-
Hauptermittler:
- Marina Frimer, MD
-
Mount Kisco, New York, Vereinigte Staaten, 10549
- Rekrutierung
- Northern Westchester Hospital
-
Hauptermittler:
- Marina Frimer, MD
-
Kontakt:
- Jemima Jacob, MPH
- Telefonnummer: 914-666-1366
- E-Mail: jjacob22@northwell.edu
-
New Hyde Park, New York, Vereinigte Staaten, 11040
- Rekrutierung
- Cohen Children's Medical Center
-
Kontakt:
- Shreya Seepersaud
- Telefonnummer: 718-470-7146
- E-Mail: sseepersaud2@northwell.edu
-
Hauptermittler:
- Marina Frimer, MD
-
New York, New York, Vereinigte Staaten, 10065
- Rekrutierung
- Manhattan Eye, Ear, and Throat Hospital
-
Hauptermittler:
- Marina Frimer, MD
-
Kontakt:
- Leila Nasr
- E-Mail: lnasr@northwell.edu
-
New York, New York, Vereinigte Staaten, 10305
- Rekrutierung
- Staten Island University Hospital
-
Hauptermittler:
- Marina Frimer, MD
-
Kontakt:
- Sammi Ruan
- Telefonnummer: 718-226-1489
- E-Mail: sruan2@northwell.edu
-
Kontakt:
- Melissa McCarthy
- Telefonnummer: 718-226-1805
- E-Mail: mccarthy22@northwell.edu
-
Rego Park, New York, Vereinigte Staaten, 11374
- Rekrutierung
- Queens Cancer Center
-
Hauptermittler:
- Marina Frimer, MD
-
Kontakt:
- Harmandeep Kaur
- Telefonnummer: 718-412-0773
- E-Mail: hkaur37@northwell.edu
-
Sleepy Hollow, New York, Vereinigte Staaten, 10591
- Rekrutierung
- Phelps Hospital
-
Hauptermittler:
- Marina Frimer, MD
-
Kontakt:
- Barbara Turner, RN
- Telefonnummer: 914-269-1949
- E-Mail: Bturner1@northwell.edu
-
Kontakt:
- Shyrley Gomez
- E-Mail: Sgomez21@northwell.edu
-
-
North Carolina
-
Chapel Hill, North Carolina, Vereinigte Staaten, 27599
- Rekrutierung
- Lineberger Comprehensive Cancer Center
-
Hauptermittler:
- Shetal Patel, MD
-
Kontakt:
- Emmie Cole
- Telefonnummer: 919-966-4432
- E-Mail: emmie_cole@med.unc.edu
-
Charlotte, North Carolina, Vereinigte Staaten, 28277
- Rekrutierung
- Atrium Health's Levine Cancer Institute
-
Hauptermittler:
- Kathryn F. Mileham, MD, FACP
-
Kontakt:
- Jenna Gregory, MS, RN
- E-Mail: Jenna.Gregory@atriumhealth.org
-
-
North Dakota
-
Bismarck, North Dakota, Vereinigte Staaten, 58501
- Rekrutierung
- Sanford Health- Bismarck
-
Kontakt:
- Peter Kurniali, MD
- Telefonnummer: 701-323-5741
- E-Mail: peter.kurniali@sanfordhealth.org
-
Hauptermittler:
- Peter Kurniali, MD
-
Fargo, North Dakota, Vereinigte Staaten, 58122
- Rekrutierung
- Sanford Health- Fargo
-
Kontakt:
- Anu Gaba, MD
- Telefonnummer: 701-234-6161
- E-Mail: anu.gaba@sanfordhealth.org
-
Hauptermittler:
- Anu Gaba, MD
-
-
Ohio
-
Cincinnati, Ohio, Vereinigte Staaten, 45219
- Rekrutierung
- University of Cincinnati Medical Center
-
Hauptermittler:
- Davendra Sohal, MD
-
Kontakt:
- Kayla Webb, MSN, RN
- Telefonnummer: 513-584-0599
- E-Mail: webb2ka@ucmail.uc.edu
-
Kettering, Ohio, Vereinigte Staaten, 45429
- Rekrutierung
- Kettering Health
-
Kontakt:
- Allison Dymacek, BSN, RN
- Telefonnummer: 937-395-8367
- E-Mail: allison.dymacek@ketteringhealth.org
-
Hauptermittler:
- Lex Leonhardt, DO
-
West Chester, Ohio, Vereinigte Staaten, 45069
- Rekrutierung
- West Chester Hospital
-
Hauptermittler:
- Trisha Wise-Draper, MD
-
Kontakt:
- Kayla Webb, MSN, RN
- Telefonnummer: 513-584-0599
- E-Mail: webb2ka@ucmail.uc.edu
-
-
Oregon
-
Portland, Oregon, Vereinigte Staaten, 97213
- Rekrutierung
- Providence Health & Services
-
Hauptermittler:
- Evthokia Hobbs, MD
-
Kontakt:
- Isa Ngirailemesang
- Telefonnummer: 971-358-2056
- E-Mail: Isa.Ngirailemesang@providence.org
-
-
Pennsylvania
-
Allentown, Pennsylvania, Vereinigte Staaten, 18103
- Rekrutierung
- Lehigh Valley Hospital - Cedar Crest
-
Kontakt:
- Telefonnummer: 734-712-3671
- E-Mail: MCRCwebsitecontactform@trinity-health.org
-
Hauptermittler:
- Maged Khalil, MD
-
Bethlehem, Pennsylvania, Vereinigte Staaten, 18017
- Rekrutierung
- Lehigh Valley Hospital- Muhlenberg
-
Hauptermittler:
- Maged Khalil, MD
-
Kontakt:
- Telefonnummer: 7347127251
- E-Mail: MCRCwebsitecontactform@trinity-health.org
-
East Stroudsburg, Pennsylvania, Vereinigte Staaten, 18301
- Rekrutierung
- Pocono Medical Center
-
Hauptermittler:
- Maged Khalil, MD
-
Kontakt:
- Telefonnummer: 7347127251
- E-Mail: MCRCwebsitecontactform@trinity-health.org
-
Hazleton, Pennsylvania, Vereinigte Staaten, 18201
- Rekrutierung
- Lehigh Valley Hospital-Hazleton
-
Hauptermittler:
- Maged Khalil, MD
-
Kontakt:
- Telefonnummer: 7347127251
- E-Mail: MCRCwebsitecontactform@trinity-health.org
-
Philadelphia, Pennsylvania, Vereinigte Staaten, 19111
- Rekrutierung
- Fox Chase Cancer Center
-
Hauptermittler:
- Margaret von Mehren, MD
-
Kontakt:
- Fathima S Sheriff
- Telefonnummer: 215-728-4094
- E-Mail: fathima.sheriff@fccc.edu
-
-
South Carolina
-
Bluffton, South Carolina, Vereinigte Staaten, 29910
- Rekrutierung
- SC Cancer Specialists at St. Joseph's/Candler Bluffton
-
Hauptermittler:
- Mark Taylor, MD
-
Kontakt:
- Stephanie Smith, RN, MSN, OCN
- Telefonnummer: 19128195723
- E-Mail: smiths1@sjchs.org
-
Bluffton, South Carolina, Vereinigte Staaten, 29910
- Rekrutierung
- St. Joseph's/Candler Smith
-
Hauptermittler:
- Mark Taylor, MD
-
Kontakt:
- Stephanie Smith, RN, MSN, OCN
- Telefonnummer: 19128195723
- E-Mail: smiths1@sjchs.org
-
Bluffton, South Carolina, Vereinigte Staaten, 29910
- Rekrutierung
- Summit Cancer Care at St. Josph's/Candler Bluffton
-
Hauptermittler:
- Mark Taylor, MD
-
Kontakt:
- Stephanie Smith, RN, MSN, OCN
- Telefonnummer: 19128195723
- E-Mail: smiths1@sjchs.org
-
Hilton Head Island, South Carolina, Vereinigte Staaten, 29926
- Rekrutierung
- South Carolina Cancer Specialists
-
Hauptermittler:
- Mark Taylor, MD
-
Kontakt:
- Stephanie Smith, RN, MSN, OCN
- Telefonnummer: 19128195723
- E-Mail: smiths1@sjchs.org
-
-
South Dakota
-
Sioux Falls, South Dakota, Vereinigte Staaten, 57104
- Rekrutierung
- Sanford Cancer Center Oncology Clinic and Pharmacy
-
Hauptermittler:
- Steven Powell, MD
-
Kontakt:
- Steven Powell, MD
- Telefonnummer: 605-328-8000
- E-Mail: steven.powell@sanfordhealth.org
-
-
Tennessee
-
Nashville, Tennessee, Vereinigte Staaten, 37203
- Rekrutierung
- Tennessee Oncology - Nashville / Sarah Cannon Research Institute
-
Kontakt:
- Ethan Trull
- Telefonnummer: 615-329-7274
- E-Mail: Ethan.Trull@SarahCannon.com
-
Hauptermittler:
- Meredith McKean, MD, MPH
-
-
Texas
-
Houston, Texas, Vereinigte Staaten, 77030
- Rekrutierung
- The University of Texas MD Anderson Cancer Center
-
Hauptermittler:
- Funda Meric-Bernstam, MD
-
Kontakt:
- Kshipra Sharma, MPH, MS
- Telefonnummer: 713-745-8431
- E-Mail: Ksharma2@MDAnderson.org
-
-
Utah
-
Cedar City, Utah, Vereinigte Staaten, 84720
- Rekrutierung
- Cedar City Hospital, SW Cancer Clinic, Sandra Maxwell Cancer Center
-
Hauptermittler:
- Ramya Thota, MD
-
Kontakt:
- Jake Kolu
- Telefonnummer: 435-705-1632
- E-Mail: Jake.Kolu@imail.org
-
Hauptermittler:
- Derrick Haslem, MD
-
Salt Lake City, Utah, Vereinigte Staaten, 84107
- Rekrutierung
- Intermountain Healthcare
-
Kontakt:
- Tracy Taylor
- Telefonnummer: 801-507-3953
- E-Mail: tracy.taylor@imail.org
-
Hauptermittler:
- Ramya Thota, M.D.
-
Hauptermittler:
- Derrick Haslem, M.D.
-
St. George, Utah, Vereinigte Staaten, 84770
- Rekrutierung
- Dixie Regional Medical Center-River Road Campus
-
Hauptermittler:
- Ramya Thota, MD
-
Kontakt:
- Jake Kolu
- Telefonnummer: 435-705-1632
- E-Mail: Jake.Kolu@imail.org
-
Hauptermittler:
- Derrick Haslem, MD
-
-
Virginia
-
Fairfax, Virginia, Vereinigte Staaten, 22042
- Rekrutierung
- Inova Schar Cancer Institute
-
Hauptermittler:
- Timothy Cannon, MD
-
Kontakt:
- Roxana Comfort, CRC
- Telefonnummer: 571-472-0628
- E-Mail: roxana.comfort@inova.org
-
-
Washington
-
Bonney Lake, Washington, Vereinigte Staaten, 98391
- Rekrutierung
- Northwest Medical Specialties
-
Kontakt:
- Jennifer Spokely
- Telefonnummer: 253-999-3701
- E-Mail: research@southsoundcare.org
-
Hauptermittler:
- Frank Senecal, MD
-
Federal Way, Washington, Vereinigte Staaten, 98003
- Rekrutierung
- Northwest Medical Specialties
-
Kontakt:
- Jennifer Spokely
- Telefonnummer: 253-999-3701
- E-Mail: research@southsoundcare.org
-
Hauptermittler:
- Frank Senecal, MD
-
Gig Harbor, Washington, Vereinigte Staaten, 98332
- Rekrutierung
- Northwest Medical Specialties
-
Kontakt:
- Jennifer Spokely
- Telefonnummer: 253-999-3701
- E-Mail: research@southsoundcare.org
-
Hauptermittler:
- Frank Senecal, MD
-
Olympia, Washington, Vereinigte Staaten, 98502
- Rekrutierung
- Northwest Medical Specialties
-
Kontakt:
- Jennifer Spokely
- Telefonnummer: 253-999-3701
- E-Mail: research@southsoundcare.org
-
Hauptermittler:
- Frank Senecal, MD
-
Puyallup, Washington, Vereinigte Staaten, 98373
- Rekrutierung
- Northwest Medical Specialties
-
Hauptermittler:
- Frank Senecal, MD
-
Kontakt:
- Jennifer Spokely
- Telefonnummer: 253-999-3701
- E-Mail: reserch@southsoundcare.org
-
Seattle, Washington, Vereinigte Staaten, 98104
- Rekrutierung
- Swedish Cancer Institute
-
Hauptermittler:
- Philip Gold, MD
-
Kontakt:
- Sidney Ching
- Telefonnummer: 206-386-3142
- E-Mail: sidney.ching@swedish.org
-
Tacoma, Washington, Vereinigte Staaten, 98405
- Rekrutierung
- Northwest Medical Specialties
-
Hauptermittler:
- Frank Senecal, MD
-
Kontakt:
- Jennifer Spokely
- Telefonnummer: 253-999-3701
- E-Mail: reserch@southsoundcare.org
-
-
Wisconsin
-
Burlington, Wisconsin, Vereinigte Staaten, 53105
- Rekrutierung
- Aurora Cancer Care - Burlington
-
Hauptermittler:
- Antony Ruggeri, MD
-
Kontakt:
- Michelle Toutloff, RN, CCRP
- Telefonnummer: 9204567880
- E-Mail: Michelle.Martin2@aah.org
-
Germantown, Wisconsin, Vereinigte Staaten, 53022
- Rekrutierung
- Aurora Health Care - Germantown Health Center
-
Hauptermittler:
- Antony Ruggeri, MD
-
Kontakt:
- Michelle Toutloff, RN, CCRP
- Telefonnummer: 9204567880
- E-Mail: Michelle.Martin2@aah.org
-
Grafton, Wisconsin, Vereinigte Staaten, 53024
- Rekrutierung
- Aurora Cancer Care - Grafton
-
Hauptermittler:
- Antony Ruggeri, MD
-
Kontakt:
- Michelle Toutloff, RN, CCRP
- Telefonnummer: 9204567880
- E-Mail: Michelle.Martin2@aah.org
-
Green Bay, Wisconsin, Vereinigte Staaten, 54311
- Rekrutierung
- Aurora BayCare Medical Center
-
Hauptermittler:
- Antony Ruggeri, MD
-
Kontakt:
- Michelle Toutloff, RN, CCRP
- Telefonnummer: 9204567880
- E-Mail: Michelle.Martin2@aah.org
-
Kenosha, Wisconsin, Vereinigte Staaten, 53142
- Rekrutierung
- Aurora Cancer Care - Kenosha South
-
Hauptermittler:
- Antony Ruggeri, MD
-
Kontakt:
- Michelle Toutloff, RN, CCRP
- Telefonnummer: 9204567880
- E-Mail: Michelle.Martin2@aah.org
-
Marinette, Wisconsin, Vereinigte Staaten, 54143
- Rekrutierung
- Aurora Bay Area Medical Center
-
Hauptermittler:
- Antony Ruggeri, MD
-
Kontakt:
- Michelle Toutloff, RN, CCRP
- Telefonnummer: 9204567880
- E-Mail: Michelle.Martin2@aah.org
-
Milwaukee, Wisconsin, Vereinigte Staaten, 53215
- Rekrutierung
- Aurora St. Luke's Medical Center
-
Hauptermittler:
- Antony Ruggeri, MD
-
Kontakt:
- Michelle M Toutloff, RN, CCRP
- Telefonnummer: 9204567880
- E-Mail: Michelle.Martin2@aah.org
-
Milwaukee, Wisconsin, Vereinigte Staaten, 53209
- Rekrutierung
- Aurora Cancer Care Milwaukee
-
Hauptermittler:
- Antony Ruggeri, MD
-
Kontakt:
- Michelle M Toutloff, RN, CCRP
- Telefonnummer: 9204567880
- E-Mail: Michelle.Martin2@aah.org
-
Milwaukee, Wisconsin, Vereinigte Staaten, 53223
- Rekrutierung
- Aurora Sinai Medical Center
-
Hauptermittler:
- Antony Ruggeri, MD
-
Kontakt:
- Michelle Toutloff, RN, CCRP
- Telefonnummer: 9204567880
- E-Mail: Michelle.Martin2@aah.org
-
Milwaukee, Wisconsin, Vereinigte Staaten, 53227
- Rekrutierung
- Aurora West Allis Medical Center
-
Hauptermittler:
- Antony Ruggeri, MD
-
Kontakt:
- Michelle Toutloff, RN, CCRP
- Telefonnummer: 9204567880
- E-Mail: Michelle.Martin2@aah.org
-
Oshkosh, Wisconsin, Vereinigte Staaten, 54904
- Rekrutierung
- Vince Lombardi Cancer Clinic - Oshkosh
-
Hauptermittler:
- Antony Ruggeri, MD
-
Kontakt:
- Michelle Toutloff, RN, CCRP
- Telefonnummer: 9204567880
- E-Mail: Michelle.Martin2@aah.org
-
Racine, Wisconsin, Vereinigte Staaten, 53406
- Rekrutierung
- Aurora Cancer Care - Racine
-
Hauptermittler:
- Antony Ruggeri, MD
-
Kontakt:
- Michelle Toutloff, RN, CCRP
- Telefonnummer: 9204567880
- E-Mail: Michelle.Martin2@aah.org
-
Sheboygan, Wisconsin, Vereinigte Staaten, 53081
- Rekrutierung
- Vince Lombardi Cancer Center
-
Hauptermittler:
- Antony Ruggeri, MD
-
Kontakt:
- Michelle Toutloff, RN, CCRP
- Telefonnummer: 9204567880
- E-Mail: Michelle.Martin2@aah.org
-
Summit, Wisconsin, Vereinigte Staaten, 53066
- Rekrutierung
- Aurora Medical Center in Summit
-
Hauptermittler:
- Antony Ruggeri, MD
-
Kontakt:
- Michelle Toutloff, RN, CCRP
- Telefonnummer: 9204567880
- E-Mail: Michelle.Martin2@aah.org
-
Two Rivers, Wisconsin, Vereinigte Staaten, 54241
- Rekrutierung
- Vince Lombardi Cancer Clinic - Two Rivers
-
Hauptermittler:
- Antony Ruggeri, MD
-
Kontakt:
- Michelle Toutloff, RN, CCRP
- Telefonnummer: 9204567880
- E-Mail: Michelle.Martin2@aah.org
-
Wauwatosa, Wisconsin, Vereinigte Staaten, 53226
- Rekrutierung
- Aurora Cancer Care - Milwaukee West
-
Hauptermittler:
- Antony Ruggeri, MD
-
Kontakt:
- Michelle Toutloff, RN, CCRP
- Telefonnummer: 920-456-7880
- E-Mail: Michelle.Martin2@aah.org
-
-
Teilnahmekriterien
Zulassungskriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
-
12 years of age or older (*Restrictions apply. Not all therapies are available for patients <18)
-
Histologically-proven locally advanced or metastatic solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma who is no longer benefiting from standard anti-cancer treatment or for whom, in the opinion of the treating physician, no such treatment is available or indicated (except under the circumstance in which the TAPUR arm is designed to provide additional evidence to support an existing FDA indication).
-
Performance status 0-2 (Per Eastern Cooperative Oncology Group (ECOG) criteria)
-
Patients must have acceptable organ function as defined below. However, as noted above, drug-specific inclusion/exclusion criteria specified in the protocol appendix for each agent will take precedence for this and all inclusion criteria:
- Absolute neutrophil count ≥ 1500 µl
- Hemoglobin ≥ 9.0 g/dl
- Platelets ≥ 75,000/µl
- Total bilirubin < 2.0 mg/ dl, except in patients with Gilbert's Syndrome
- Aspartate aminotransferase (AST) serum glutamic-oxaloacetic transaminase (SGOT) and alanine aminotransferase (ALT) serum glutamic-pyruvic transaminase (SGPT) < 2.5 x institutional upper limit of normal (ULN) (or < 5 x ULN in patients with known hepatic metastases)
- Serum creatinine ≤ 1.5 × ULN or calculated or measured creatinine clearance ≥ 50 mL/min/1.73 m2
-
Patients must have disease that can be objectively measured by physical, laboratory or radiographic exam (per RECIST v1.1 for solid tumor, Lugano criteria for non-Hodgkin lymphoma or International Myeloma Working Group criteria for multiple myeloma).
-
Results must be available from a genomic test or immunohistochemistry (IHC) test for protein expression performed in a Clinical Laboratory Improvement Amendments (CLIA)-certified and College of American Pathologists (CAP)-accredited or New York State accredited (for labs offering services to residents of NY) laboratory. Labs that have registered the test with the NIH Genetic Testing Registry or that provide a report that has been designated as optimized for TAPUR participation are preferred, but not required. The genomic or IHC test used to qualify a patient for participation in TAPUR may have been performed on any specimen of the patient's tumor obtained at any point during the patient's care at the discretion of the patient's treating physician. Genomic assays performed on cell-free DNA in plasma ("liquid biopsies") will also be acceptable if the genomic analysis is performed in a laboratory that meets the criteria described above.
-
Ability to understand and the willingness to sign a written informed consent/assent document.
-
Have a tumor genomic profile for which single agent treatment with one of the FDA approved targeted anti-cancer drugs included in this study has potential clinical benefit based on the criteria described in protocol.
-
For orally administered drugs, the patient must be able to swallow and tolerate oral medication and must have no known malabsorption syndrome.
-
Because of the risks of drug treatment to the developing fetus, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) for the duration of study participation, and for four months following completion of study therapy. Should a woman become pregnant or suspect she is pregnant while participating in this study or if she is the partner of a male participant in this study and becomes pregnant while he is participating in this study, she should inform her or her partner's treating physician immediately as well as her obstetrician. Female study patients who become pregnant must immediately discontinue treatment with any study therapy. Male patients should avoid impregnating a female partner. Male study patients, even if surgically sterilized, (i.e. post-vasectomy) must agree to one of the following: practice effective barrier contraception during the entire study treatment period and for a specified amount of time the last dose of study treatment, or completely abstain from sexual intercourse.
Note: TAPUR does not explicitly exclude any type of solid tumor, but the patient must have measurable and evaluable disease per RECIST v1.1.
Exclusion Criteria:
- Patients whose disease is not measurable or cannot be assessed by radiographic imaging or physical examination (e.g., elevated serum tumor marker only) are not eligible
- Patients with primary brain tumors or new, untreated or progressive leptomeningeal metastases are excluded
- Patients with previously treated brain metastases or previously treated leptomeningeal disease are eligible, provided that the patient has not experienced a seizure or had a clinically significant change in neurological status within the 1 months prior to registration. All patients with previously treated brain metastases must be clinically stable for at least 1 month after completion of treatment and off steroid treatment for one month prior to study enrollment.
- Patients with known progressive brain metastases are eligible but additional eligibility criteria apply.
Note: there are additional exclusion criteria that may apply
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Nicht randomisiert
- Interventionsmodell: Einzelgruppenzuweisung
- Maskierung: Keine (Offenes Etikett)
Anzahl der Arme
Waffen und Interventionen
Teilnehmergruppe / ArmTeilnehmergruppe / Arm |
Intervention / BehandlungIntervention / Behandlung |
|---|---|
|
Sonstiges: Group 5 (CSF1R,PDGFR,VEGFR)
Participants receive sunitinib - dosage, frequency and duration per label; acceptable genomic matches include CSF1R, PDGFR, VEGFR1/2/3, KIT, FLT-3, RET, FGFR1/2/3, VHL amplifications or mutations |
drug
Andere Namen:
|
|
Sonstiges: Group 8 (ERBB2)
Participants receive trastuzumab and pertuzumab - dosage, frequency and duration per label; acceptable genomic matches include ERBB2 amplification or overexpression, and specific ERBB2 mutations |
drug
Andere Namen:
|
|
Sonstiges: Group 9 (BRAF V600E/D/K/R)
Participants receive vemurafenib and cobimetinib - dosage, frequency and duration per label; acceptable genomic matches include BRAF V600E/D/K/R mutations |
drug
Andere Namen:
|
|
Sonstiges: Group 14 (BRCA1/2; ATM)
Participants receive olaparib - dosage, frequency and duration per label; acceptable genomic matches include germline or somatic BRCA1/2 inactivating mutations; ATM mutations or deletions |
drug
Andere Namen:
|
|
Sonstiges: Group 16 (MSI-H, high mutational load and others)
Participants receive nivolumab and ipilimumab - dosage, frequency and duration per label; acceptable genomic matches include MSI high status, high tumor mutational burden, MLH1, MSH2/6, PMS2, EPCAM mutations, specific POLE or POLD1 mutations, BRCA1/2, ATM, MSH3, PMS1, MLH3, EXO1, RFC1/2/3/4/5, PCNA, RPA1/2/3/4, and SSBP1 loss of function mutations |
drug
Andere Namen:
|
|
Sonstiges: Group 17 (CDKN2A, CDK4, CDK6)
Participants receive abemaciclib - dosage, frequency and duration per label; acceptable genomic matches include CDKN2A loss or mutation, CDK4, CDK6 amplifications, CDKN2B loss or mutation |
drug
Andere Namen:
|
|
Sonstiges: Group 19 (BRCA1/2, PALB2)
Participants receive talazoparib - dosage, frequency and duration per label; acceptable genomic matches include germline or somatic BRCA1/2 and PALB2 mutations |
drug
Andere Namen:
|
|
Sonstiges: Group 21 (BRCA1/2, PALB2, ATM, and others)
Participants receive atezolizumab plus talazoparib - dosage, frequency and duration per label; acceptable genomic matches include germline or somatic mutations in BRCA1/2, PALB2, ATM, ATR, CHEK2, FANCA, RAD51C, NBN, MLH1, MRE11A, CDK12; positive genomic instability score reported on the Myriad MyChoice CDx test; or Genomic Loss of Heterozygosity (LOH) Score above threshold as reported on a FoundationOne CDx test or another qualifying test for TAPUR with MTB approval |
drug
Andere Namen:
|
|
Sonstiges: Group 24 (ERBB2)
Participants receive tucatinib plus trastuzumab SC - dosage, frequency and duration per label; acceptable genomic matches include ERBB2 amplification or overexpression, and specific ERBB2 mutations |
drug
Andere Namen:
|
|
Sonstiges: Group 25
Participants receive futibatinib- dosage, frequency and duration per label; acceptable genomic matches include FGFR 1,2,3,4 fusion (or other rearrangement) or mutation |
drug
Andere Namen:
|
|
Sonstiges: Group 26 (BRAF V600 E mutation )
Participants receive Dabrafenib plus Trametinib - dosage, frequency and duration per label; acceptable genomic matches include BRAF V600 E mutation . |
Drug
Andere Namen:
|
|
Sonstiges: Group 27 (ERBB2 amplification, ERBB2 (HER2) IHC2+ or IHC3+ overexpression)
Participants receive Fam-trastuzumab deruxtecan-nxki (ENHERTU®) - dosage, frequency and duration per label; acceptable genomic matches include ERBB2 amplification, For NSCLC Only-ERBB2 (HER2) IHC2+ or IHC3+ overexpression without ERBB2 amplification) |
Drug
Andere Namen:
|
Was misst die Studie?
Primäre Ergebnismessungen
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Objective Response Rate defined as % of participants in a cohort with complete or partial response or with stable disease according to standard response criteria
Zeitfenster: Assessed at 16 weeks of treatment
|
Each cohort includes participants with the same tumor type, genomic variant and study drug. For solid tumors, the Response Evaluation Criteria for Solid Tumors (RECIST) criteria will be used, for non-Hodgkin Lymphoma, the Lugano Criteria will be used, and for multiple myeloma, the International Uniform Response Criteria for Multiple Myeloma will be used. |
Assessed at 16 weeks of treatment
|
Sekundäre Ergebnismessungen
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Overall survival (OS)
Zeitfenster: Duration of survival from registration on study until death from any cause, assessed throughout end of study, up to 3 years
|
OS will be estimated using the Kaplan-Meier method |
Duration of survival from registration on study until death from any cause, assessed throughout end of study, up to 3 years
|
Mitarbeiter und Ermittler
Sponsor
Sponsor
Mitarbeiter
Mitarbeiter
Publikationen und hilfreiche Links
Allgemeine Veröffentlichungen
- Alva AS, Mangat PK, Garrett-Mayer E, Halabi S, Hansra D, Calfa CJ, Khalil MF, Ahn ER, Cannon TL, Crilley P, Fisher JG, Haslem DS, Shrestha S, Antonelli KR, Butler NL, Warren SL, Rygiel AL, Ranasinghe S, Bruinooge SS, Schilsky RL. Pembrolizumab in Patients With Metastatic Breast Cancer With High Tumor Mutational Burden: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. J Clin Oncol. 2021 Aug 1;39(22):2443-2451. doi: 10.1200/JCO.20.02923. Epub 2021 Apr 12.
- Fisher JG, Tait D, Garrett-Mayer E, Halabi S, Mangat PK, Schink JC, Alvarez RH, Veljovich D, Cannon TL, Crilley PA, Pollock T, Calfa CJ, Al Baghdadi T, Thota R, Fleming N, Cotta JA, Rygiel AL, Warren SL, Schilsky RL. Cetuximab in Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Ovarian Cancer Without KRAS, NRAS, or BRAF Mutations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. Target Oncol. 2020 Dec;15(6):733-741. doi: 10.1007/s11523-020-00753-7.
- Al Baghdadi T, Garrett-Mayer E, Halabi S, Mangat PK, Rich P, Ahn ER, Chai S, Rygiel AL, Osayameh O, Antonelli KR, Islam S, Bruinooge SS, Schilsky RL. Sunitinib in Patients with Metastatic Colorectal Cancer (mCRC) with FLT-3 Amplification: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. Target Oncol. 2020 Dec;15(6):743-750. doi: 10.1007/s11523-020-00752-8.
- Gupta R, Meric-Bernstam F, Rothe M, Garrett-Mayer E, Mangat PK, D'Andre S, Ahn ER, O'Lone R, Halabi S, Grantham GN, Schilsky RL. Pertuzumab Plus Trastuzumab in Patients With Colorectal Cancer With ERBB2 Amplification or ERBB2/3 Mutations: Results From the TAPUR Study. JCO Precis Oncol. 2022 Oct;6:e2200306. doi: 10.1200/PO.22.00306.
- Mangat PK, Kirkwood MK, Hinshaw DC, Garrett-Mayer E, Schilsky RL. Prevalence of targetable genomic alterations among a diverse population participating in the ASCO TAPUR Study. NPJ Precis Oncol. 2025 Jul 3;9(1):222. doi: 10.1038/s41698-025-00962-1.
- Worden FP, Pisick E, Rothe M, Mangat PK, Garrett-Mayer E, Khalil MF, Carrizosa DR, Bauman JR, Leidner RS, Duvivier HL, Fu S, Park MS, Yost KJ, Calfa CJ, Marr AS, Balmanoukian AS, Behl D, Cannon TL, Nabell L, Powell SF, Thota R, Hinshaw DC, Gregory A, Grantham GN, Halabi S, Schilsky RL. Palbociclib in Patients With Head and Neck Cancer and Other Tumors With CDKN2A Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study. JCO Precis Oncol. 2024 Oct;8:e2400477. doi: 10.1200/PO-24-00477. Epub 2024 Oct 16.
- Schuetze S, Rothe M, Mangat PK, Garrett-Mayer E, Meric-Bernstam F, Calfa CJ, Farrington LC, Livingston MB, Wentzel K, Behl D, Kier Y, Marr AS, von Mehren M, Press JZ, Thota R, Grantham GN, Gregory A, Hinshaw DC, Halabi S, Schilsky RL. Palbociclib in Patients With Soft Tissue Sarcoma With CDK4 Amplifications: Results From the Targeted Agent and Profiling Utilization Registry Study. JCO Precis Oncol. 2024 Jul;8:e2400219. doi: 10.1200/PO.24.00219.
- Srkalovic G, Rothe M, Mangat PK, Garrett-Mayer E, Ahn ER, Brouse G, Chan J, Mehmi I, Khalil M, Duvivier HL, Gaba A, Leuva H, Thota R, Yost KJ, Grantham GN, Gregory A, Hinshaw DC, Halabi S, Schilsky RL. Talazoparib in Patients With Solid Tumors With BRCA1/2 Mutation: Results From the Targeted Agent and Profiling Utilization Registry Study. JCO Precis Oncol. 2024 Jun;8:e2400026. doi: 10.1200/PO.24.00026.
- Cannon TL, Rothe M, Mangat PK, Garrett-Mayer E, Chiu VK, Hwang J, Vijayvergia N, Alese OB, Dib EG, Duvivier HL, Klute KA, Sahai V, Ahn ER, Bedano P, Behl D, Sinclair S, Thota R, Urba WJ, Yang ES, Grantham GN, Hinshaw DC, Gregory A, Halabi S, Schilsky RL. Pertuzumab Plus Trastuzumab in Patients With Biliary Tract Cancer With ERBB2/3 Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study. J Clin Oncol. 2024 Sep 20;42(27):3228-3237. doi: 10.1200/JCO.23.02078. Epub 2024 May 15.
- Perez JK, Kleber J, Rothe M, Mangat P, Garrett-Mayer E, Schilsky RL. Concordance in Molecular Tumor Board Case Reviews in the ASCO TAPUR Study. JCO Precis Oncol. 2024 Mar;8:e2300615. doi: 10.1200/PO.23.00615.
- Calfa CJ, Rothe M, Mangat PK, Garrett-Mayer E, Ahn ER, Burness ML, Gogineni K, Rohatgi N, Al Baghdadi T, Conlin A, Gaba A, Hamid O, Krishnamurthy J, Gavini NJ, Gold PJ, Rodon J, Rueter J, Thota R, Grantham GN, Hinshaw DC, Gregory A, Halabi S, Schilsky RL. Sunitinib in Patients With Breast Cancer With FGFR1 or FGFR2 Amplifications or Mutations: Results From the Targeted Agent and Profiling Utilization Registry Study. JCO Precis Oncol. 2024 Feb;8:e2300513. doi: 10.1200/PO.23.00513.
- Meric-Bernstam F, Rothe M, Mangat PK, Garrett-Mayer E, Gutierrez R, Ahn ER, Cannon TL, Powell S, Krauss JC, Reynolds CM, von Mehren M, Behl D, Calfa CJ, Duvivier HL, Kaplan HG, Livingston MB, Sharma MR, Urba WJ, Grantham GN, Hinshaw DC, Gregory A, Halabi S, Schilsky RL. Cobimetinib Plus Vemurafenib in Patients With Solid Tumors With BRAF Mutations: Results From the Targeted Agent and Profiling Utilization Registry Study. JCO Precis Oncol. 2023 Sep;7:e2300385. doi: 10.1200/PO.23.00385.
- Rohatgi N, Rothe M, Mangat PK, Garrett-Mayer E, Meric-Bernstam F, Pisick E, Alese OB, Reynolds CM, Thota R, Vaccaro GM, von Mehren M, Arend RC, Chiu VK, Duvivier HL, Gold PJ, Hack K, Marr AS, Winer A, Grantham GN, Hinshaw DC, Gregory A, Halabi S, Schilsky RL. Nivolumab Plus Ipilimumab in Patients With Solid Tumors With ATM Mutations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. JCO Precis Oncol. 2023 Sep;7:e2300279. doi: 10.1200/PO.23.00279.
- Duvivier HL, Rothe M, Mangat PK, Garrett-Mayer E, Ahn ER, Al Baghdadi T, Alva AS, Dublis SA, Cannon TL, Calfa CJ, Li R, Behl D, Chiu VK, Gold PJ, Marr AS, Mileham KF, Powell SF, Rodon J, Thota R, Grantham GN, Gregory A, Hinshaw DC, Halabi S, Schilsky RL. Pembrolizumab in Patients With Tumors With High Tumor Mutational Burden: Results From the Targeted Agent and Profiling Utilization Registry Study. J Clin Oncol. 2023 Nov 20;41(33):5140-5150. doi: 10.1200/JCO.23.00702. Epub 2023 Aug 10.
- Mangat PK, Garrett-Mayer E, Perez JK, Schilsky RL. The Targeted Agent and Profiling Utilization Registry Study: A pragmatic clinical trial. Clin Trials. 2023 Dec;20(6):699-707. doi: 10.1177/17407745231182013. Epub 2023 Jul 25.
- Ganti AK, Rothe M, Mangat PK, Garrett-Mayer E, Dib EG, Duvivier HL, Ahn ER, Behl D, Borghaei H, Balmanoukian AS, Gaba A, Li R, Osei-Boateng K, Thota R, Grantham GN, Gregory A, Halabi S, Schilsky RL. Pertuzumab Plus Trastuzumab in Patients With Lung Cancer With ERBB2 Mutation or Amplification: Results From the Targeted Agent and Profiling Utilization Registry Study. JCO Precis Oncol. 2023 Jun;7:e2300041. doi: 10.1200/PO.23.00041.
- Ahn ER, Rothe M, Mangat PK, Garrett-Mayer E, Ali-Ahmad HM, Chan J, Maitland ML, Patel SR, Reese Z, Balmanoukian AS, Drescher CW, Li R, Tsimberidou AM, Leath CA 3rd, O'Lone R, Grantham GN, Halabi S, Schilsky RL. Pertuzumab Plus Trastuzumab in Patients With Endometrial Cancer With ERBB2/3 Amplification, Overexpression, or Mutation: Results From the TAPUR Study. JCO Precis Oncol. 2023 Apr;7:e2200609. doi: 10.1200/PO.22.00609.
- Yang ES, Halabi S, Rothe M, Garrett-Mayer E, Mangat PK, Pisick E, Dib E, Burgess EF, Zakem M, Rohatgi N, Bilen MA, O'Lone R, Grantham GN, Schilsky RL. Olaparib in Patients With Metastatic Prostate Cancer With BRCA1/2 Mutation: Results From the TAPUR Study. JCO Precis Oncol. 2023 Feb;7:e2200505. doi: 10.1200/PO.22.00505.
- Carrizosa DR, Rothe M, Mangat PK, Garrett-Mayer E, Behl D, Adesunloye B, Pisick E, Beekman KW, Dotan E, Akce M, Alese OB, Sahai V, Klute KA, Aragon-Ching JB, Cooper KA, Thota R, Meric-Bernstam F, Hosein PJ, Maestas EC, Moyers JT, Powell S, Zhao S, Hobbs E, Rueter J, Sohal DPS, Taylor MA, Hinshaw DC, Gregory A, Grantham GN, Halabi S, Schilsky RL. Olaparib in Patients With Solid Tumors With ATM Alterations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. JCO Precis Oncol. 2026 Jan;10:e2500716. doi: 10.1200/PO-25-00716. Epub 2026 Jan 15.
- Al Baghdadi T, Rothe M, Mangat PK, Garrett-Mayer E, Crysler OV, Mileham KF, Farrington LC, Adesunloye B, Dublis SA, Astsaturov I, Calfa CJ, Bleeker J, Khalil M, Thota R, Cannon TL, Alese OB, Gold PJ, Hafez N, Baron AD, Meric-Bernstam F, Hobbs E, Marr AS, Rueter J, Tawfik B, Hinshaw DC, Gregory A, Grantham GN, Halabi S, Schilsky RL. Olaparib in Patients With Solid Tumors With BRCA1/2 Alterations: Results From The Targeted Agent and Profiling Utilization Registry (TAPUR) Study. JCO Precis Oncol. 2025 Oct;9:e2500649. doi: 10.1200/PO-25-00649. Epub 2025 Oct 16.
- Cobain EF, Rothe M, Garrett-Mayer E, Cannon TL, Chan JK, Mileham KF, Adesunloye B, Calfa CJ, Alese OB, Butler KY, Dib EG, Pisick E, Bell M, Klute KA, Mehmi I, Meric-Bernstam F, Mangat PK, Hinshaw DC, Gregory A, Grantham GN, Halabi S, Schilsky RL. Nivolumab Plus Ipilimumab in Patients With Solid Tumors With High Tumor Mutation Burden: Results From the Targeted Agent and Profiling Utilization Registry Study. JCO Precis Oncol. 2026 Apr;10(4):e2501205. doi: 10.1200/PO-25-01205. Epub 2026 Apr 30.
- Pisick E, Rothe M, Garrett-Mayer E, Srkalovic G, Chan JK, Calfa CJ, Leath CA 3rd, Marr AS, Gold PJ, Crane EK, Moyers JT, Yost Butler K, Gaba A, Thota R, Harnden KK, Alese OB, Jain A, Rueter J, Gill S, George TJ, Frimer M, Kayali F, Mangat PK, Hinshaw DC, Gregory A, Grantham GN, Halabi S, Schilsky RL. Temsirolimus in Patients With Solid Tumors With PIK3CA Mutations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. JCO Precis Oncol. 2026 Apr;10(4):e2500985. doi: 10.1200/PO-25-00985. Epub 2026 Apr 22.
- Veljovich DS, Rothe M, Garrett-Mayer E, Ali-Ahmad HM, Naumann RW, Siedel J, Chan JK, Gregory A, Pisick E, Adesunloye B, Arend RC, Bell M, Frimer M, Tawfik B, Thota R, Tsimberidou AM, Mangat PK, Hinshaw DC, Gregory A, Grantham GN, Halabi S, Schilsky RL. Palbociclib in Patients With Ovarian Cancer With CDKN2A Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study. JCO Precis Oncol. 2026 Jul;10(7):e2600456. doi: 10.1200/PO-26-00456. Epub 2026 Jul 15.
- Diamond-Rossi SA, Rothe M, Garrett-Mayer E, Pisick E, Bleeker J, Ganti AK, Meric-Bernstam F, Moyers JT, Nair SG, Kadakia KC, Rohatgi N, Sahai V, Vijayvergia N, Gold PJ, Sharma MR, Hinshaw DC, Gregory A, Grantham GN, Halabi S, Schilsky RL. Cobimetinib + Vemurafenib in Patients With BRAF V600E-Mutant Papillary Thyroid and Biliary Tract Cancers: Results From the TAPUR Study. JCO Precis Oncol. 2026 Oct;10(10):e2600703. doi: 10.1200/PO-26-00703. Epub 2026 Oct 16.
- Srkalovic G, Rothe M, Garrett-Mayer E, Mileham KF, Adesunloye B, Pisick E, Leath CA 3rd, Colocci N, Chen MD, Meric-Bernstam F, Marr AS, Alese OB, Powell S, Rueter J, Benyounes A, Pontious C, Lewis MA, Thomas GW, Kier Y, Calfa CJ, von Mehren M, Acoba JD, Hinshaw DC, Gregory A, Grantham GN, Halabi S, Schilsky RL. Sunitinib in Patients With Various Solid Tumors With FGFR1/2 Alterations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. JCO Precis Oncol. 2026 Oct;10(10):e2600454. doi: 10.1200/PO-26-00454. Epub 2026 Oct 7.
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Studienbeginn
Primärer Abschluss (Geschätzt)
Primärer Abschluss
Studienabschluss (Geschätzt)
Studienabschluss
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Geschätzt)
Zuerst gepostet
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes Update gepostet
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
- Gefäßerkrankungen
- Herz-Kreislauf-Erkrankungen
- Erkrankungen des Immunsystems
- Neubildungen nach histologischem Typ
- Hämatologische Erkrankungen
- Lymphatische Erkrankungen
- Lymphoproliferative Erkrankungen
- Immunproliferative Erkrankungen
- Lymphom
- Neubildungen, Plasmazelle
- Hämostasestörungen
- Paraproteinämien
- Bluteiweißstörungen
- Hämorrhagische Störungen
- Hämische und lymphatische Krankheiten
- Neubildungen
- Multiples Myelom
- Lymphom, Non-Hodgkin
- Aminosäuren, Peptide und Proteine
- Proteine
- Schwefelverbindungen
- Organische Chemikalien
- Heterocyclische Verbindungen, 1-Ring
- Heterocyclische Verbindungen
- Heterocyclische Verbindungen, 2-Ring
- Heterocyclische Verbindungen, Fusionsring
- Azolen
- Amides
- Indolen
- Antikörper, monoklonal, humanisiert
- Antikörper, monoklonal
- Antikörper
- Immunglobuline
- Immunoproteine
- Blutproteine
- Serumglobuline
- Globuline
- Pyrrolen
- Sulfonamide
- Sulfone
- Trastuzumab
- Sunitinib
- Nivolumab
- Ipilimumab
- Vemurafenib
- Abemaciclib
- Pertuzumab
- Dabrafenib
- Trametinib
- Atezolizumab
- Olaparib
- Talazoparib
- Cobimetinib
- Tucatinib
- Futibatinib
Andere Studien-ID-Nummern
Andere Studien-ID-Nummern
- Pro00014171
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .